Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia, a genetic condition that causes severely short stature and disproportionate growth.
Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia, a genetic condition that causes severely short stature and disproportionate growth.
Achondroplasia is caused by a genetic mutation that increases the activity of a certain growth regulation gene called fibroblast growth factor receptor 3 (FGFR3). The overabundance of protein coded by the FGFR3 gene prevents normal bone growth. Vosoritide works by binding to a specific receptor called natriuretic peptide receptor B that reduces the growth regulation gene's activity, thus allowing for bone growth.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).